Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • NPPA Relief: Sun...

    NPPA Relief: Sun Pharma anti-cancer drug Gemcitabine gets price control exemption

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-11-14T11:30:08+05:30  |  Updated On 14 Nov 2019 11:30 AM IST
    NPPA Relief: Sun Pharma anti-cancer drug Gemcitabine gets price control exemption

    New Delhi: Through a recent order, the apex drug price regulator, National Pharmaceutical Pricing Authority (NPPA) has exempted drugmaker, Sun Pharmaceuticals Ltd.'s (Sun Pharma) oncology drug Gemcitabine Hydrochloride Injection from price control citing that the drug fulfils the criterion of a new drug under Para 32 of the Drug Price Control Order.


    Under paragraph 32 of the Drug (Price Control) Order, 2013, the NPPA can exempt drugs from price control which are either new or have a new delivery system that is developed through indigenous research.


    The decision to exempt Sun Pharma's anti-cancer drug came during the 70th NPPA meeting held in October 2019, following a plea submitted by the firm. The firm sought exemption for its ready to use infusion bags Gemcitabine Hydrochloride Injection 10mg/ml (Ready to use infusion bags 1200mg/120ml, 1400mg/140ml & 1600mg/160ml) which was duly approved by the office of Central Drugs Standard Control Organisation (CDSCO) as ‘new drug’ under Rule 122(E) of the Drugs and Cosmetics Act and Rules thereunder, and patented by The Patent Office, India under the Patents Act, 1970 (Patent No. 296771 and Date of Grant: 14.05.2018).


    This came after the authority deliberated upon the matter in detail and noted that the application has been received under para 32 (ii) of DPCO 2013. The imperatives of para 32(ii) of DPCO 2013 are:




    • The drug should be a new drug as per the definition provided in rule 122E of the Drugs and Cosmetic Rules, 1945

    • The drug is produced by a new process

    • Developed through indigenous Research and Development, and

    • patented under the Indian Patent Act, 1970 (process patent)


    The matter was referred to the Multidisciplinary Committee of Experts that stated that the submission of the documents by the firm meets the requirements of para 32 (ii) of DPCO, 2013.


    Thereafter, it was noted that the NPPA had referred the applications to Standing National Committee on Medicines for revision of NLEM (SNCM) with a request to examine the products from the perspective of any significant therapeutic advantage and increased efficacy that may merit exemption under para 32 of DPCO 2013.


    Earlier NPPA had refused to give it relief in terms of price cap exemption for its anti-cancer gemcitabine hydrochloride injection from price caps set by the government. However, it had decided to refer to its application to ‘Standing National Committee on Medicines for revision of NLEM’ with a request to examine the products from the perspective of any significant therapeutic advantage and increased efficacy that may merit an exemption under para 32 of DPCO, 2013.


    Also Read: Setback to Sun Pharma: NPPA refuses to give relief of price cap exemption for Gemcitabine


    SNCM stated that there is no clinical study to suggest that Gemcitabine hydrochloride injection 10mg/ml (ready to use infusion bags 1200mg/120ml, 1400mg140ml and 1600mg/160 ml) offers significant therapeutic advantage and increases efficacy. The availability of gemcitabine in infusion bags is only helpful in the practical sense of administration to patients.


    Recently NPPA discussed and noted that establishing significant therapeutic advantage and increased efficacy is not a requirement or pre-condition for obtaining an exemption under para 32(ii) of DPCO, 2013 and further as the company fulfils the conditions as per para 32(ii) of DPCO2013.


    Subsequently, NPPA decided that exemption may be granted to Sun Pharma under para 32(ii) of DPCO, 2013 for their product Ready to use infusion bags Gemcitabine hydrochloride injection 10mg/ml (Ready to use infusion bags 1200mg/120ml, 1400mg/140ml and 1600mg/160ml).

    cancerCDSCOCentral Drugs Standard Control OrganisationDPCODrug (Price Control) OrderGemcitabineNational Pharmaceutical Pricing AuthorityNPPAoncology drugprice control exemptionSun Pharma

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok